T-Cell Killer Opens New Approach to Rheumatoid Arthritis

(MedPage Today) — CHICAGO — An investigational monoclonal antibody drug targeting the PD-1 ligand on T cells was a winner in a phase II rheumatoid arthritis (RA) trial.
Twelve weeks of treatment with the agent, called rosnilimab, led to a…